Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Royalty Pharma
Pharmaceutical Preparation ManufacturingUnited StatesNASDAQ: RPRX
Last verified 28 days agoroyaltypharma.com
Royalty Pharma, a leading entity in the Pharmaceutical Preparation Manufacturing industry, is headquartered in the United States. Founded in 1996, the company has established itself as a prominent player in the biopharmaceutical sector, focusing on acquiring and managing revenue-generating pharmaceutical royalties. With a robust portfolio that includes innovative therapies across various therapeutic areas, Royalty Pharma distinguishes itself through its unique business model that supports drug development while providing financial returns to investors.
The company operates primarily in North America and Europe, leveraging its extensive network to enhance access to cutting-edge treatments. Notable achievements include strategic partnerships with major pharmaceutical companies, positioning Royalty Pharma as a key contributor to the advancement of life-saving medications. With a commitment to innovation and patient access, Royalty Pharma continues to shape the future of healthcare.
31
DitchCarbon score
-11 vs industry average
Royalty Pharma’s score of 31 is lower than 43% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Royalty Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2027
20202021202220232024202520262027
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Royalty Pharma's reported carbon emissions
Royalty Pharma, a US-based pharmaceutical preparation manufacturing company, reported its Scope 3 emissions from investments in 2024 to be approximately 23,266,000 kg CO2e. This figure represents a decrease from 2023, where Scope 3 investments were about 32,002,000 kg CO2e. In 2022, these emissions were approximately 19,610,000 kg CO2e, following approximately 18,445,000 kg CO2e in 2021. Royalty Pharma has not disclosed Scope 1 or Scope 2 emissions data.
Assessing Royalty Pharma as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Royalty Pharma and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Royalty Pharma’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Royalty Pharma yet.
Scope 3 top emissions categories
1 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Royalty Pharma28 days ago
31
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more